ArticleCurrent oncology (Toronto, Ont.)2022
Prognostic Factors of Low-Grade Gliomas in Adults.
Article in Current oncology (Toronto, Ont.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 16 citations in OpenAlex.
- Gene regulatory network analysis identifies dysregulation of hypoxia pathways as contributing to glioblastoma treatment resistance in females.Biology of sex differences · 2026Article
- Multimodal techniques for maximal safe resection of IDH-mutant low-grade glioma involving corpus callosum, a retrospective study and prognosis analysis.Chinese neurosurgical journal · 2026Article
- Evaluating work activity and societal burden in patients with grade 2 IDH-mutant glioma.Neuro-oncology practice · 2026Article
- Gene regulatory network analysis identifies dysregulation of hypoxia pathways as contributing to glioblastoma multiforme treatment resistance in females.medRxiv : the preprint server for health sciences · 2026Article
- From Classical to Emerging Biomarkers of Brain and Central Nervous System Tumors. An Evidence-Based Review with a Focus on Gliomas.Cellular and molecular neurobiology · 2026Review
- Asleep motor mapping in resected low-grade gliomas -a population based multicenter study.Brain & spine · 2026Article
- Multimodal artificial intelligence in glioma management: integrating neuroimaging and hematologic biomarkers for precision oncology.Frontiers in oncology · 2026Review
- Survival of nervous system tumors in a Colombian population cancer registry.Journal of neuro-oncology · 2025Article
- The role of the Ki-67 labelling index as an independent prognostic factor in indonesian glioma patients.Histology and histopathology · 2025Article
- Wild-Type TP53 Predicts Poor Prognosis in Lower-Grade Glioma via TP53-CXCL14-GATA3 Axis.Journal of molecular neuroscience : MN · 2025Article
- Assessing the Validity of Diffusion Weighted Imaging Models: A Study in Patients with Post-Surgical Lower-Grade Glioma.Journal of clinical medicine · 2025Article
- Immune checkpoints in immune response to glioma: two sides of the same coin.Frontiers in immunology · 2025Review
- Radiosurgery for Hypothalamic Gliomas: A Case Report and Clinical Guidelines Form a Neurosurgical Center of Excellence.Journal of personalized medicine · 2024Article
- A gene signature predicting prognosis of patients with lower-grade gliomas receiving temozolomide therapy.Discover oncology · 2023Article
- A modified melanoma-molGPA scoring model: assessment of survival after and efficacy of different radiotherapy modalities in patients with melanoma brain metastases.Discover oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adult low-grade gliomas are a rare and aggressive pathology of the central nervous system. Some of their characteristics contribute to the patient's life expectancy and to their management. This study aimed to characterize and identify the main prognostic factors of low-grade gliomas. The six-year retrospective study statistically analyzed the demographic, imaging, and morphogenetic characteristics of the patient group through appropriate parameters. Immunohistochemical tests were performed: IDH1, Ki-67, p53, and Nestin, as well as FISH tests on the CDKN2A gene and 1p/19q codeletion. The pathology was prevalent in females, with patients having an average age of 56.31 years. The average tumor volume was 41.61 cm
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.